Industry News
Pharmaceutical Industry News

3 Drugs Older People May Be Overusing
Not all older people need these medications, and they can carry increased risks.
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.
Keke Palmer joins Sanofi to share…
Keke Palmer joins Sanofi to share her decision to immunize her son with Beyfortus ahead of the coming respiratory syncytial virus (RSV) season.
The Breztri ad prompts viewers to…
The Breztri ad prompts viewers to "put a LAMA to work" by depicting an AI-generated llama and his barnyard colleagues working a late night in the office.
The Search for New Cures Is Broken
It is too hard for medical researchers to launch clinical trials.
After Jenny Pearson’s daughter…
After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful,” Pearson recalled to Fierce. But a follow-up scan a year later, just days before
Daiichi Sankyo subsidiary American…
Daiichi Sankyo subsidiary American Regent is launching a recall of three lots of generic epinephrine as it becomes one of the latest manufacturers to face headaches over particulate contamination in its drug products.
Move over AbbVie and Johnson &…
Move over AbbVie and Johnson & Johnson, we have a new and surprising leading drug in the pharma ad spending space.
GSK, Roche and Novartis continued…
GSK, Roche and Novartis continued their dealmaking spree with Asian companies. Three midsized Asian biopharmas reached MFN deals with the White House. Akeso and Summit's ivonescimab delivered a head-to-head overall survival win against Keytruda. And
Why aren’t diagnostic-driven…
Why aren’t diagnostic-driven therapies reaching enough patients?
Following a string of customer…
Following a string of customer complaints, a Form 483 and a recall this past spring, a Fresenius manufacturing unit in Utah is contending with a warning letter from the FDA.
The social media collaboration…
The social media collaboration ties into Novartis' "you know your MS best" messaging, which encourages patients to keep track of changes in their disease.
Two votes of confidence from…
Two votes of confidence from leaders at the FDA’s Office of Clinical Evaluation and the Oncology Center of Excellence sealed Replimune’s fate, overruling review staffers’ concerns and paving the way for last month’s accelerated nod
About two years ago, a…
About two years ago, a head-to-head progression-free survival win made Akeso and Summit’s ivonescimab—and the PD-1xVEGF class—the most promising agent to replace Keytruda. Now, that same trial has met its overall survival endpoint, but to
A Guide to Covid, Flu and R.S.V. Vaccines This Fall
Major medical groups released new recommendations on who should get the shots, citing a lack of strong guidance from the federal government.
The new business unit is centered…
The new business unit is centered on four core capabilities, which includes AI-enhanced scientific intelligence, omnichannel "scientific ecosystems," and more.
RNA-based vaccines and…
RNA-based vaccines and therapeutics may have faced a bumpy road in the U.S. recently, but a major new federal investment proves the government is still betting big on its future.
Novartis could cut about 130 jobs…
Novartis could cut about 130 jobs in Switzerland as it rethinks its biologics technical development and production footprint in Basel.
On the back of a heart-helping win…
On the back of a heart-helping win for the 11-year-old Repatha last fall, Amgen has continued to deepen the evidence on its PCSK9 inhibitor’s ability to cut cardiovascular risks in many patients.
Why are so many eligible patients…
Why are so many eligible patients still missing the therapies designed for them?


